Roche (SIX: RO, ROG; OTCQX: RHHBY) has introduced its proprietary Sequencing by Expansion (SBX) technology, establishing a new category in next-generation sequencing (NGS). This innovative approach promises ultra-rapid, high-throughput sequencing that is both flexible and scalable across various genomic applications.

Next-generation sequencing is critical for advancing our understanding of genetics, genomics, and cell biology, particularly in complex diseases such as cancer, immune disorders, and neurodegenerative conditions. Roche’s SBX technology addresses the limitations of existing sequencing solutions by delivering unparalleled speed, efficiency, and flexibility.

At the heart of SBX technology is a novel biochemical process that encodes DNA or RNA sequences into an expanded surrogate polymer known as an Xpandomer. These Xpandomers are fifty times longer than the original molecule and incorporate high signal-to-noise reporters, ensuring clear signals with minimal background interference. This process facilitates highly accurate single-molecule nanopore sequencing using a Complementary Metal Oxide Semiconductor (CMOS)-based sensor module, enhancing both speed and efficiency.

“Solving the signal-to-noise challenge is a key efficiency driver for the technology,” said Mark Kokoris, Head of Roche’s SBX Technology. “With this capability, we can flexibly operate across different throughput scales using the same system, providing a significant advantage to users.”

SBX technology’s unique combination of speed, accuracy, and flexibility makes it ideal for a wide range of genomic applications, including whole genome sequencing, whole exome sequencing, and RNA sequencing. Its advanced CMOS sensor module enables real-time base calling and analysis, allowing researchers to process multiple samples simultaneously. This scalability ensures cost-efficient sequencing for both small-scale studies and large projects involving thousands of samples.

“The science behind SBX technology represents a significant breakthrough that addresses the limitations of existing sequencing solutions,” said Matt Sause, CEO of Roche Diagnostics. “By integrating and enhancing these technologies, Roche’s SBX offers unparalleled speed, efficiency, and flexibility, revolutionizing the use of sequencing in research and healthcare.”

Originally developed by Mark Kokoris and Robert McRuer, SBX technology was pioneered by Stratos Genomics, a company acquired by Roche in 2020. By overcoming traditional sequencing limitations, SBX has the potential to drive broader adoption in both research and clinical labs, accelerating discoveries and improving healthcare outcomes.

Also Read: Aakash Healthcare and Medtronic Launch North India’s First Specialised Vein Clinic

Roche’s commitment to advancing next-generation sequencing is further demonstrated through its complementary offerings. These include the KAPA sample preparation products for DNA and RNA library prep and target enrichment, as well as the AVENIO Edge system, which provides an automated solution for KAPA kits. Roche’s AVENIO assays also deliver robust oncology solutions, including the recently approved AVENIO Tumor Tissue CGP Automated Kit, developed in collaboration with Foundation Medicine.

With its cutting-edge approach, Roche’s SBX technology promises to transform genomic research and clinical applications, paving the way for new insights into disease mechanisms and personalized healthcare solutions.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!